Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;107(5):426-431.e1.
doi: 10.1016/j.anai.2011.05.020. Epub 2011 Jun 17.

Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2

Affiliations

Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2

Tolly G Epstein et al. Ann Allergy Asthma Immunol. 2011 Nov.

Abstract

Background: Incidences of subcutaneous immunotherapy (SCIT) related systemic reactions (SRs) and fatal reactions (FRs) are not well defined, nor are delayed-onset SRs and their treatment.

Objectives: To estimate SCIT-related SRs/FRs, and the incidence and treatment of delayed-onset SRs.

Methods: In 2008 and 2009, American Academy of Allergy, Asthma & Immunology (AAAAI) and American College of Allergy Asthma & Immunology (ACAAI) members completed a survey about SCIT-related SR severity (grade 1 = mild; grade 2 = moderate; grade 3 = severe anaphylaxis). In 2009, members reported the time of onset and use of epinephrine (EPI), with early onset defined as beginning ≤30 minutes, and delayed onset beginning more than 30 minutes after injections.

Results: As in year 1, no FRs were reported during year 2 (630 total practices responded). Among 267 practices providing data on the timing of SRs, 1,816 early-onset SRs (86%) and 289 (14%) delayed-onset SRs were reported. Fifteen percent (226/1,519) of grade 1, 10% (54/538) of grade 2, and 12.5% (9/72) of grade 3 SRs were delayed-onset. Among early-onset SRs, EPI was given for 71% of grade 1, 93% of grade 2, and 94% of grade 3s. Among delayed-onset SRs, EPI was given for 56% of grade 1, 67% of grade 2, and 100% of grade 3s (P = .0008 for difference in EPI administration based on severity; P = .07 based on time of onset).

Conclusions: Delayed-onset SRs are less frequent than previously reported. Epinephrine was given less frequently for grades 1 and 2 (but not grade 3) delayed-onset SRs compared with early-onset SRs. Further study of prescribing self-injectable EPI for SCIT patients in the event of delayed-onset SRs may be warranted.

PubMed Disclaimer

Conflict of interest statement

Disclosures: David I. Bernstein, MD-Clinical investigator Merck, Schering Plough, Greer, ALK, Stallergenes; Consultant—Merck, ALK, Schering Plough. Tolly G. Epstein, MD, Karen Murphy-Berendts, BS, and Gary M. Liss, MD have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Administration of epinephrine (EPI) in early versus delayed-onset systemic reactions (SRs). Early-onset SRs are those occurring at ≤30 minutes after injection; Delayed-onset SRs are those occurring at > 30 minutes. Gr1 = grade 1; Gr 2 = grade 2; Gr3 = grade 3. Data regarding timing, SR severity, and EPI use were available for 219 practices. For early-onset SRs, EPI was given for 912/1,293 grade 1 SRs, 450/484 grade 2 SRs, and 59/63 grade 3 SRs. For delayed-onset SRs, EPI was given for 126/226 grade 1 SRs, 36/54 grade 2 SRs, and 9/9 grade 3 SRs. *P = .0008 for the difference in EPI use based on SR severity. **P = .07 for the difference in EPI use based on the time of onset of the reaction.

References

    1. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79:660–677. - PubMed
    1. Matloff SM, Bailit IW, Parks P, Madden N, Greineder DK. Systemic reactions to immunotherapy. Allergy Proc. 1993;14:347–350. - PubMed
    1. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34:527–531. - PubMed
    1. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Eur Ann Allergy Clin Immunol 2004;36:52–55. - PubMed
    1. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol. 1993;92:6–15. - PubMed

Publication types